RJ 8201
Alternative Names: RJ-8201Latest Information Update: 20 Sep 2023
At a glance
- Originator Nanjing Ruijie Pharma
- Class Antipsoriatics; Small molecules
- Mechanism of Action Serum-glucocorticoid regulated kinase modulators; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 07 Jul 2023 Preclinical trials in Psoriasis in China (PO), prior to July 2023 (Nanjing Ruijie Pharmaceuticals pipeline, July 2023)
- 07 Jul 2023 Pharmacodynamics data from a preclinical studies in psoriasis released by Nanjing Ruijie Pharmaceuticals (Nanjing Ruijie Pharmaceuticals pipeline, July 2023)
- 29 Jun 2023 Nanjing Ruijie Pharmaceuticals has patents pending for RJ 8201 in USA